Trials / Completed
CompletedNCT00151437
Canadian Pegvisomant Compassionate Study In Acromegalic Patients
A Multi-Center, Open-Label Study For The Compassionate Use Of Pegvisomant In Acromegalic Patients Refractory To Conventional Therapy and For Patients Who Received The Product During The Clinical Development Program.
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 30 (planned)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purposes of this study are: 1) to provide SOMAVERT for compassionate use to patients with acromegaly or who have completed clinical trials and were responsive, and 2) to evaluate the safety and tolerability of SOMAVERT.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pegvisomant treatment | |
| PROCEDURE | Medical History, demographics | |
| PROCEDURE | Sign and symptoms: questionnaire | |
| PROCEDURE | Blood tests: IGF-1, AST/ALT/ALP/TBIL, GTT | |
| PROCEDURE | MRI |
Timeline
- Start date
- 2004-11-01
- Completion
- 2007-04-01
- First posted
- 2005-09-09
- Last updated
- 2008-04-24
Locations
5 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT00151437. Inclusion in this directory is not an endorsement.